Sage Therapeutics

Sage Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing novel treatments for mood disorders and neurological conditions through the modulation of GABA and NMDA receptor systems. The company was founded in 2010 by Dr. Steven M. Paul and Dr. Michael W. Jann.

Overview

Sage Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing novel treatments for mood disorders and neurological conditions through the modulation of GABA and NMDA receptor systems. The company was founded in 2010 by Dr. Steven M. Paul and Dr. Michael W. Jann.

Overview

Sage Therapeutics pioneered the development of GABA-A receptor modulators and NMDA receptor antagonists for the treatment of depression, epilepsy, and other CNS disorders. The company's platform leverages neurosteroid science to develop treatments targeting the brain's inhibitory and excitatory signaling systems["@sagea"].

Funding

• IPO: 2014 (NASDAQ: SAGE)
• Market Cap: ~$2B (2026)
• Acquired: 2023 by Biogen ($14.6B)

Corporate Highlights

• Founded: 2010
• Headquarters: Cambridge, Massachusetts
• NASDAQ: SAGE
• Employees: Approximately 600
• Key Partner: Biogen (zuranolone collaboration)

History and Development

Founding and Early Development (2010-2015)

Clinical Development (2015-2019)

• 2015: Advanced brexanolone into Phase 2/3 for postpartum depression
• 2017: Initiated Phase 3 for brexanolone (now ZULRESSO)
• 2018: Announced positive Phase 3 results for postpartum depression
• 2019: FDA approval of ZULRESSO

Biogen Partnership and Expansion (2020-Present)

• 2020: Biogen partnership for zuranolone - $1.5 billion upfront
• 2021-2023: Advanced zuranolone for major depressive disorder
• 2024: FDA approval of ZURZUVAE (oral zuranolone)

Approved Products

ZULRESSO (Brexanolone)

ZULRESSO represents a breakthrough in postpartum depression treatment[@zulresso]:

• Indication: Postpartum depression (PPD) in adults
• FDA Approval: March 2019
• Mechanism: GABA-A receptor positive allosteric modulator (synthetic allopregnanolone)
• Significance: First and only FDA-approved intravenous treatment for postpartum depression
• Administration: 60-hour continuous IV infusion in certified healthcare facilities under REMS

• Rapid reduction in HAMD-17 scores (within days)
• Sustained response through 30-day follow-up
• No suicidal ideation worsening

ZURZUVAE (Zuranolone)

ZURZUVAE provides oral treatment option for PPD[@zurzuvae]:

• Indication: Postpartum depression (oral formulation)
• FDA Approval: March 2024
• Mechanism: GABA-A receptor positive allosteric modulator
• Significance: First oral treatment for postpartum depression
• Dosing: 14-day course (50mg once daily)

Pipeline Programs

Clinical Development

| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| Zuranolone | Major depressive disorder | GABA-A modulator | Phase 3[@zuranolone] |
| Zuranolone | Generalized anxiety disorder | GABA-A modulator | Phase 3 |
| SAGE-718 | Alzheimer's disease (cognitive) | NMDA receptor antagonist | Phase 2 |
| SAGE-718 | Parkinson's disease (cognitive) | NMDA receptor antagonist | Phase 2 |
| SAGE-718 | Huntington's disease | NMDA receptor antagonist | Phase 2 |
| SAGE-324 | Essential tremor | GABA-A modulator | Phase 2 |
| SAGE-689 | CNS disorders | GABA-A modulator | Phase 1 |

Science and Technology

Neurosteroid Platform

• Allopregnanolone: Natural GABA-A modulator with antidepressant effects
• Brexanolone: Synthetic allopregnanolone for IV administration
• Zuranolone: Modified version optimized for oral bioavailability

GABA-A Receptor Modulation

• Positive allosteric modulators enhance GABA signaling
• Unlike benzodiazepines, neurosteroid modulators have different binding sites
• May offer benefits without tolerance or dependence

NMDA Receptor Antagonism

• Ketamine: Rapid-acting but with dissociative effects
• SAGE-718: May offer cognitive benefits without psychedelic effects
• Potential for neurodegenerative disease applications[@nmda]

Neurological Relevance

Sage's pipeline addresses major unmet needs in neurology and psychiatry[@sageb]:

SAGE-718 for Neurodegenerative Cognitive Impairment

SAGE-718 (Navoximod) is an NMDA receptor antagonist with potential for:

• Alzheimer's Disease: Cognitive impairment affects 40-50% of AD patients; no approved disease-modifying treatments
• Parkinson's Disease Dementia: Affects up to 80% of PD patients with long disease duration
• Huntington's Disease: Cognitive decline is a core symptom

GABA Platform Applications

The GABA-A receptor modulators have applications beyond mood disorders:

• Essential Tremor: SAGE-324 in Phase 2 - a common movement disorder
• Epilepsy: Original zuranolone program - complex partial seizures
• Neuroprotection: GABAergic mechanisms may protect neurons from excitotoxicity

Financial Highlights

• Market Cap: Approximately $3 billion USD (2025)
• Biogen Partnership: $1.5 billion upfront, $1.6 billion milestones
• ZURZUVAE Projected Peak Sales: $500 million - $1 billion USD
• [Postpartum Depression](/genes/ar)
• Major Depressive Disorder
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)
• [Huntington's Disease](/diseases/huntingtons)
• [Essential Tremor](/diseases/essential-tremor)
• [GABA Signaling](/mechanisms/gaba-signaling)
• [NMDA Signaling](/genes/gnal)
• Brexanolone
• [Zuranolone](/genes/ran)
• [Biogen](/companies/biogen)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References